SCHEMBL8058845

SCHEMBL8058845

O=C(O)C(OP(=O)(O)CCc1cccc2[nH]ccc12)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
PARP1 P09874 1/20 0.35
APAF1 O14727 1/20 0.35
POLB P06746 1/20 0.35
RECQL P46063 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.35
MPO P05164 1/20 0.35
TSHR P16473 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
HIF1A Q16665 1/20 0.35
MCL1 Q07820 1/20 0.35
GLS O94925 2/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5054362 0.89 HPGDS (0.38) HPGDSSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5060251 0.86 SMN1; SMN2 (0.48) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL5059954 0.82 ACP3 (0.44) L3MBTL1MCL1TDP1CYP1A2
SCHEMBL7606891 0.81 PARP1 (0.42) HPGDSSMN1; SMN2MAPTKDM4EPARP1
SCHEMBL5054472 0.81 ALDH1A1 (0.47) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL8520179 0.80 SRC (0.39) SMN1; SMN2MAPTMEN1KMT2APARP1
SCHEMBL7608451 0.78 HPGDS (0.40) HPGDSMEN1KMT2APOLBMCL1
SCHEMBL5054488 0.77 SMN1; SMN2 (0.50) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL7053859 0.77 ACP3 (0.43) MCL1TDP1
SCHEMBL5054433 0.76 ACP3 (0.43) MCL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP disclosed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO disclosed